Skip to Content

More

Emsam Approved - Bristol-Myers Squibb Company/Somerset Pharmaceuticals, Inc. - Treatment for Major Depressive Disorder

Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. Emsam is indicated for the treatment of major depressive disorder (MDD) in adults.

Posted: February 2006

Related Articles:

Somerset Files Response to Emsam Action Letter - June 16, 2005
Mylan Laboratories and Watson Pharmaceuticals Announce Receipt of "Approvable" Letter for Emsam - February 2, 2004

Emsam (selegiline) FDA Approval History

More News Resources

Drug Status

Recently Approved

Lokelma Lokelma (sodium zirconium cyclosilicate) is a crystalline lattice potassium ion-trap indicated for...
Aimovig Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated...
Lucemyra Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated...
Retacrit Retacrit (epoetin alfa-epbx) is an erythropoiesis-stimulating agent (ESA) biosimilar to...

Available RSS Feeds

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated May 1st, 2018), Cerner Multum™ (updated May 2nd, 2018), Wolters Kluwer™ (updated May 1st, 2018) and others. To view content sources and attributions, please refer to our editorial policy.